The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

Veteran CDMO executive to guide next phase of global expansion and operational excellence for lentiviral vector manufacturer.

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...

Explore the latest advances in R&D and manufacturing of in vivo lentiviral vectors. Discover the challenges faced in this process and the innovative solutions being developed in the field.

“The applications of lentiviral vectors are diverse,” she says, pointing out that while 65% of the CDMO’s customers are developing immunotherapies, like CAR-Ts, TCRs, NK-CARs, NK-TCRs, TILs ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform.. The deal will see AstraZeneca scoop up all ...

BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to address this need through a novel approach of inserting a functional copy of the CFTR gene in the DNA of ...

Discover how innovative production and clarification products improve lentiviral vector generation. Share. The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, ...

Scaling Lentiviral Vector Manufacturing for Optimal Productivity Explore a comprehensive guide to standardizing large scale production and clarification of lentiviral vectors. Share. Viral vectors are ...

Spanish gene therapy specialist VIVEbiotech has named Patricio Massera as its new president, bringing in a seasoned CDMO ...

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ...